- You are here:
- Home
- >
- Guidelines in Practice
- >
- Volume 16 - Edition 9
News
News – September 2013
NICE publishes guidelines on acute kidney injury and autism
NICE has released Clinical Guideline (CG) 169 on acute kidney injury up to the point of renal replacement therapy. The condition is seen in 13%–18% of all people admitted to hospital and has a major impact on healthcare resources with costs to the NHS estimated to be between £434 million and £620 million per year. CG169 covers the following key areas:
- assessing risk of acute kidney injury
- preventing acute kidney injury
- detecting acute kidney injury
- identifying the cause(s) of acute kidney injury
- managing acute kidney injury
- information and support for carers.
NICE has also announced the release of CG170 on autism in children and young people. The recommendations cover:
- general principles of care
- families and carers, and assessing their needs
- specific interventions for the core features of autism
- interventions for:
- behaviour that challenges
- life skills, including coping strategies
- coexisting problems
- transition to adult services.
Four new quality standards released by NICE
NICE has announced new quality standards aimed at driving and measuring priority quality improvements within four specific clinical areas.
Quality Standard (QS) 40 covers the assessment and management of psoriasis in children, young people, and adults. Psoriasis has an estimated prevalence in the UK of around 1.3%–2.2% and has a significant impact on health and wellbeing.
The identification and management of familial hypercholesterolaemia in adults, young people, and children is covered in QS41. More than 80% of the 120,000 people estimated to be affected by this condition are currently undiagnosed and untreated.
Quality Standard 42 describes the areas for quality improvement in the diagnosis and management of primary headache disorders and medication overuse headache in adults and young people aged 12 years and older.
Finally, QS43 covers smoking cessation, including support for people to stop smoking and also for those people seeking access to smoking cessation services. Smoking remains the main cause of preventable illness and premature death in England.
News in brief—NHS Evidence has published a new Evidence Update on nutrition support in adults
Evidence Updates provide a summary of selected new evidence published since the literature search was last conducted for their associated guidance. The key points presented in Evidence Update 46 have been determined not to have any potential impact on the recommendations within NICE Clinical Guideline 32, Nutrition support in adults: oral nutrition support, enteral tube feeding and parenteral nutrition. Twenty‑three pieces of new evidence were prioritised for review for the Evidence Update.
News in brief—Managing schizophrenia: a booklet for patients, carers and their families has been published by SIGN
The booklet aims to make adult patients and their families aware of the treatment and care people should expect to receive when they have been diagnosed with schizophrenia, and is based on the recommendations from SIGN guideline 131, Management of schizophrenia. The booklet also explains how patients can help themselves to stay well.
News in brief—The European Society of Cardiology (ESC) has announced the release of four new clinical guidelines at ESC Congress 2013
The new guidelines are on:
- the management of stable coronary artery disease
- diabetes, pre-diabetes, and cardiovascular diseases, developed with the European Association for the Study of Diabetes
- cardiac pacing and cardiac resynchronisation therapy
- the management of arterial hypertension.
‘Pocket’ versions of the guidelines are also available on mobile devices.
News in brief—verolimus is not recommended by NICE in recently published Technology Appraisal (TA) 295
Verolimus is not recommended for use in combination with exemestane, for postmenopausal women with advanced breast cancer who meet the specific criteria outlined in the guidance. The guidance states that women currently receiving everolimus for advanced breast cancer should be able to continue treatment until they and their clinician feels it is appropriate to stop.
Please to rate this article, view others comments or make your own.
